136 related articles for article (PubMed ID: 26116017)
21. ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2
Kar A; Liu B; Gutierrez-Hartmann A
Anticancer Res; 2017 Dec; 37(12):6583-6591. PubMed ID: 29187433
[TBL] [Abstract][Full Text] [Related]
22. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract][Full Text] [Related]
23. Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction.
Sadeghirizi A; Yazdanparast R; Aghazadeh S
Tumour Biol; 2016 May; 37(5):6737-47. PubMed ID: 26662109
[TBL] [Abstract][Full Text] [Related]
24. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
25. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.
Murad R; Avanes A; Ma X; Geng S; Mortazavi A; Momand J
Gene; 2021 Oct; 799():145808. PubMed ID: 34224831
[TBL] [Abstract][Full Text] [Related]
26. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
27. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
[TBL] [Abstract][Full Text] [Related]
28. Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1.
Woo J; Kim JB; Cho T; Yoo EH; Moon BI; Kwon H; Lim W
PLoS One; 2021; 16(9):e0257298. PubMed ID: 34525121
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
30. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2019 Feb; 26(1-2):1-10. PubMed ID: 29925897
[TBL] [Abstract][Full Text] [Related]
31. Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.
Oliveras-Ferraros C; Fernández-Arroyo S; Vazquez-Martin A; Lozano-Sánchez J; Cufí S; Joven J; Micol V; Fernández-Gutiérrez A; Segura-Carretero A; Menendez JA
Int J Oncol; 2011 Jun; 38(6):1533-47. PubMed ID: 21455577
[TBL] [Abstract][Full Text] [Related]
32. Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR.
Yang L; Higashisaka K; Shimoda M; Haga Y; Sekine N; Tsujino H; Nagano K; Shimazu K; Tsutsumi Y
Biochem Biophys Res Commun; 2022 Jan; 588():175-181. PubMed ID: 34959190
[TBL] [Abstract][Full Text] [Related]
33. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.
Zuo Q; Liu J; Zhang J; Wu M; Guo L; Liao W
Sci Rep; 2015 Jun; 5():11634. PubMed ID: 26108989
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of H2O2-induced cell death through FOXO1 modulation by EUK-172 in SK-N-MC cells.
Gheysarzadeh A; Yazdanparast R
Eur J Pharmacol; 2012 Dec; 697(1-3):47-52. PubMed ID: 23041154
[TBL] [Abstract][Full Text] [Related]
35. α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways.
Mason JK; Klaire S; Kharotia S; Wiggins AK; Thompson LU
Lipids Health Dis; 2015 Aug; 14():91. PubMed ID: 26282560
[TBL] [Abstract][Full Text] [Related]
36. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
37. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
Fujita T; Doihara H; Washio K; Kawasaki K; Takabatake D; Takahashi H; Tsukuda K; Ogasawara Y; Shimizu N
Anticancer Drugs; 2006 Apr; 17(4):455-62. PubMed ID: 16550004
[TBL] [Abstract][Full Text] [Related]
40. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]